Securian Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $949K | Hold |
7,554
| – | – | 0.03% | 445 |
|
|
2025
Q1 | $835K | Sell |
7,554
-100
| -1% | -$11.1K | 0.03% | 475 |
|
|
2024
Q4 | $1.04M | Sell |
7,654
-198
| -3% | -$27K | 0.03% | 417 |
|
|
2024
Q3 | $905K | Sell |
7,852
-174
| -2% | -$20K | 0.03% | 475 |
|
|
2024
Q2 | $1.1M | Sell |
8,026
-123
| -2% | -$16.9K | 0.03% | 385 |
|
|
2024
Q1 | $1.12M | Sell |
8,149
-122
| -1% | -$16.8K | 0.03% | 397 |
|
|
2023
Q4 | $1.09M | Hold |
8,271
| – | – | 0.03% | 411 |
|
|
2023
Q3 | $930K | Sell |
8,271
-421
| -5% | -$47.4K | 0.03% | 450 |
|
|
2023
Q2 | $820K | Sell |
8,692
-142
| -2% | -$13.4K | 0.02% | 524 |
|
|
2023
Q1 | $894K | Hold |
8,834
| – | – | 0.02% | 497 |
|
|
2022
Q4 | $1.06M | Buy |
8,834
+121
| +1% | +$14.5K | 0.03% | 452 |
|
|
2022
Q3 | $925K | Hold |
8,713
| – | – | 0.03% | 464 |
|
|
2022
Q2 | $849K | Buy |
8,713
+225
| +3% | +$21.9K | 0.02% | 546 |
|
|
2022
Q1 | $796K | Hold |
8,488
| – | – | 0.02% | 611 |
|
|
2021
Q4 | $723K | Hold |
8,488
| – | – | 0.01% | 656 |
|
|
2021
Q3 | $814K | Sell |
8,488
-201
| -2% | -$19.3K | 0.02% | 602 |
|
|
2021
Q2 | $846K | Sell |
8,689
-171
| -2% | -$16.6K | 0.02% | 613 |
|
|
2021
Q1 | $862K | Buy |
+8,860
| New | +$862K | 0.02% | 601 |
|